Editorial
Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S1
(October 2019)
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S2
(October 2019)
Does bisphosphonate treatment reduce the risk of future cancer?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S3
(October 2019)
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S4
(October 2019)
Perineural invasion in oral cancer: challenges, controversies and clinical impact
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S5
(October 2019)
Recent changes in the American Joint Commission Cancer staging of human papilloma virus related oropharyngeal cancer: validating the present and envisioning the future
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S6
(October 2019)
The dawn of a universal language for an emerging malignancy
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S7
(October 2019)
The 8th Edition of the American Joint Committee on Cancer (AJCC8) Staging Manual: any improvement in the prognostication of oral tongue cancer?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S8
(October 2019)
Considering sarcoma staging systems and their implications to personalized care
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S9
(October 2019)
Occult breast cancer: the uncommon presentation of a common disease
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S10
(October 2019)
Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S11
(October 2019)
Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S12
(October 2019)
Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S13
(October 2019)
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S14
(October 2019)
What can National Registry data tell us about occult breast cancer?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S15
(October 2019)
Impact of hypochloremia in resected colorectal cancer patients
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S16
(October 2019)
A step ahead on CTHRC1, and not just reinventing the wheel!
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S17
(October 2019)
Editorial Commentary
Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S18
(October 2019)
AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S19
(October 2019)
Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S20
(October 2019)
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S21
(October 2019)
Chemotherapy of pancreatic cancer in patients with poor performance
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S22
(October 2019)
Perioperative safety in patients with resectable synchronous colorectal liver metastases
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S23
(October 2019)
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S24
(October 2019)
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S25
(October 2019)
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S26
(October 2019)
Letter to the Editor
A closer look at the staging of soft tissue sarcomas in an era of personalized medicine
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S27
(October 2019)
Obituary
In memory of Dr. Henry T. Lynch
Chinese Clinical Oncology
2019;
8
(Suppl 1)
:S28
(October 2019)
Disclosure:
The supplement was published without any sponsorship or funding.